Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00150332

Enrollment

Registered

2005-09-08

Start date

2003-01-31

Completion date

2006-01-31

Last updated

2011-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections, Nosocomial

Brief summary

Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan

Interventions

DRUGlinezolid

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Healthy volunteers

Inclusion criteria

* infection due to methicillin-resistant Staphylococcus aureus

Exclusion criteria

* hypersensitivity to linezolid

Design outcomes

Primary

Measure	Time frame
Resolution of infection at the time of completion of therapy	—

Secondary

Measure	Time frame
Adverse events	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026